Accelerating drug development for simple and complex drug programmes
When it comes to complex drug programmes, the challenges in achieving clinical and commercial success are even greater.
List view / Grid view
When it comes to complex drug programmes, the challenges in achieving clinical and commercial success are even greater.
In this Guide to Outsourcing, EPR explores trends in outsourcing of regulatory activities, Quotient Sciences discusses how to accelerate drug development and Associates of Cape Cod International looks at sustainable bacterial endotoxin testing.
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
New investment provides substantial new funding to fuel the next stage of Quotient’s growth.
Quotient Clinical, the drug development services organisation, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research...